Blagborough, A.M.A.M.BlagboroughMusiychuk, K.K.MusiychukBi, H.H.BiJones, R.M.R.M.JonesChichester, J.A.J.A.ChichesterStreatfield, S.S.StreatfieldSala, K.A.K.A.SalaZakutansky, S.E.S.E.ZakutanskyUpton, L.M.L.M.UptonSinden, R.E.R.E.SindenBrian, I.I.BrianBiswas, S.S.BiswasSattabonkot, J.J.SattabonkotYusibov, V.V.Yusibov2022-03-052022-03-052016https://publica.fraunhofer.de/handle/publica/24680310.1016/j.vaccine.2016.05.007Malaria transmission blocking (TB) vaccines (TBVs) directed against proteins expressed on the sexual stages of Plasmodium parasites are a potentially effective means to reduce transmission. Antibodies induced by TBVs block parasite development in the mosquito, and thus inhibit transmission to further human hosts. The ookinete surface protein P25 is a primary target for TBV development. Recently, transient expression in plants using hybrid viral vectors has demonstrated potential as a strategy for cost-effective and scalable production of recombinant vaccines. Using a plant virus-based expression system, we produced recombinant P25 protein of Plasmodium vivax (Pvs25) in Nicotiana benthamiana fused to a modified lichenase carrier protein. This candidate vaccine, Pvs25-FhCMB, was purified, characterized and evaluated for immunogenicity and efficacy using multiple adjuvants in a transgenic rodent model.en616journal article